Pages
Products

AAV9 Virus-Like Particles (Empty Capsids)

For research use only. Not intended for any clinical use.
Cat.No.
VLP-AAV006
Description
AAV9 virus-like particles are empty capsids of AAV serotype 9 that do not contain any genomic material and can be used as reference materials and other applications.
Shipping
Dry ice
Storage
-80˚C

Background

Case Study

Publications

Q & A

Customer Reviews

AAV9, or adeno-associated virus serotype 9, is a viral vector commonly used in gene therapy. Adeno-associated viruses (AAV) are small viruses that can infect humans and some other primates, but they do not cause disease, making them a relatively safe tool for delivering therapeutic genes to cells. AAV9 is particularly known for its ability to cross the blood-brain barrier, which makes it particularly suitable for targeting the central nervous system. In addition, it has a broad tropism, meaning that it can infect a variety of cell types, including neurons, muscle cells, and heart cells. This versatility makes AAV9 a popular choice for treating a range of genetic diseases, such as spinal muscular atrophy (SMA), certain muscular dystrophies, and some lysosomal storage diseases. AAV9 virus-like particles (VLPs), often called empty capsids, are non-infectious particles that resemble natural AAV9 but do not contain any genomic material. These particles have attracted a lot of attention in both basic research and therapeutic fields because of their unique properties and potential applications. AAV9 empty capsids are structurally identical to their full capsids, with the same protein shell or capsid. The capsid is primarily composed of three viral proteins: VP1, VP2, and VP3, which self-assemble to form a stable icosahedral structure. However, unlike the complete capsid, AAV9 VLPs do not carry the viral genome. This renders them incapable of initiating infection or replication, making them safe tools for a variety of experimental and clinical uses.

There are 13 different adeno-associated virus (AAV) serotypes that are structurally homologous and similar in their capsid proteins (VP1 to -3) in amino acid sequence. However, AAV9 is one of the most commonly studied vectors for use as a gene therapy vector. This is in part due to the ability of AAV9 to cross the blood-brain barrier and readily transduce a variety of tissues, including the central nervous system. Here, researchers report on the structures of AAV9 capsids determined at endosomal pH (7.4, 6.0, 5.5, and 4.0) using cryo-electron microscopy and three-dimensional image reconstruction, as well as AAV9 capsids with terminal galactose attached at pH 7.4 and 5.5. They observed for the first time that acidification induces externalization of the VP3 and possibly VP2 N termini, which may be a prelude to externalization of VP1u at pH 4.0, which is critical for lysosomal membrane disruption. Furthermore, structural studies of the AAV9-galactose interaction revealed that AAV9 remains attached to its glycan receptor at pH 5.5 in late endosomes. This interaction significantly alters the conformational stability of the VP variable region I, as well as the kinetics associated with the externalization of the VP N terminus.

WT AAV9 virus-like particles (VLPs) were purified and dialyzed to four different pHs, mimicking those encountered during endosomal maturation. AAV9 VLPs of each pH stage remained intact and, consequently, could be vitrified and subjected to data collection and structure determination by cryoEM. Researchers have obtained near-atomic, high-resolution 3D structures of the WT AAV9 capsid at the four pHs examined, with resolutions of 2.8 (pH 7.4, PDB ID 7MT0), 2.7 (pH 6.0, PDB ID 7MTG), 2.8 (pH 5.5, PDB ID 7MTP), and 3.0 Å (pH 4.0, PDB ID 7MTW), respectively (Figure 1).

Figure 1. Structural studies of the AAV9 virus-like particles (VLPs) at four different pHs, representing the acidification stages of endosome maturation.Figure 1. Structural studies of the AAV9 virus-like particles (VLPs) at four different pHs, representing the acidification stages of endosome maturation. (Penzes J J, et al., 2021)

Customer Q&As
Does Creative Biogene’s AAV preparations belong to in-vivo grade?

A: Yes.Our AAV controls are purified and come ready-to-use for both in vitro and in vivo applications.

What is the QC (quality control) method for testing AAV in Creative Biogene?

A: We provide qPCR-based titer as the primary method to determine whether the packaging/purification process is successful or not.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Safety

The product is very safe and causes a very mild immune response.

United States

01/25/2022

Works Very Well

The product is available as a concentrated pellet in PBS and is well suited for in vivo applications or serum-sensitive cultures.

United States

09/21/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Quick Inquiry

Inquiry